



Moderna's Commitment to Vaccines and Therapeutics Access

Updated June 2024

Moderna is committed to working on multiple levels to optimize the impact of mRNA vaccines and therapeutics. Our commitment to access and pricing reflects a few basic principles:

- Moderna will invest in R&D in areas of unmet medical need.
- Moderna is committed to developing a broad portfolio of mRNA medicines to address epidemiological challenges worldwide.
- Moderna will work to include communities in our development programs that have historically been underrepresented in clinical research, as well as those that are disproportionately impacted by the respective diseases.
- Moderna is committed to systematically evaluating late-stage R&D programs to identify which of our mRNA medicines will benefit low-and lower middle-income countries and develop access plans.
- Moderna will price its mRNA medicines through differential pricing frameworks.
- Moderna is committed to collaborating with global, regional, and local partners to provide broad access.